Stay updated on Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial
Sign up to get notified when there's something new on the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page.

Latest updates to the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe study record history gains a new Revision: v3.7.0 entry, while the older Revision: v3.6.6 entry is removed from the visible history.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedA new revision entry, Revision: v3.6.6, was added to the study's record history and the previous entry for v3.6.5 was removed. This reflects an update to the version history of the study record.SummaryDifference0.1%

- Check51 days agoChange DetectedRevision v3.6.5 was added and v3.6.4 removed in the page history, indicating a new version of the record history rather than changes to study details.SummaryDifference0.1%

- Check66 days agoChange DetectedThe revision label was updated from v3.6.3 to v3.6.4, reflecting a new build of the page. No study content or functionality is affected.SummaryDifference0.1%

- Check87 days agoChange DetectedThe history now includes a new entry for Revision: v3.6.3 and removes the previous v3.6.2 entry, reflecting an updated software release in the page's history.SummaryDifference0.1%

- Check95 days agoChange DetectedThe page footer revision tag was updated from v3.6.0 to v3.6.2, indicating a newer version of the study record history page; this is a metadata update with no changes to the displayed study data.SummaryDifference0.1%

Stay in the know with updates to Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page.